Persistently high exhaled nitric oxide and loss of lung function in controlled asthma

Allergology International

Volumn 65, Issue 3, 2016, Pages 266-271

  Matsunaga, Kazuto ^a   Hirano, Tsunahiko ^a   Oka, Asako ^b   Ito, Kousuke ^a   Edakuni, Nobutaka ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adult asthma; Airflow limitation; Airway inflammation; Exhaled nitric oxide; Remodeling

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; LEUKOTRIENE; NITRIC OXIDE; THEOPHYLLINE;

ADULT; ARTICLE; ASTHMA; BODY MASS; EOSINOPHIL COUNT; EXHALATION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; DISEASE COURSE; FOLLOW UP; LUNG FUNCTION TEST; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADULT; ASTHMA; DISEASE PROGRESSION; EXHALATION; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84955606833     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.1016/j.alit.2015.12.006     Document Type: Article

References (43)

1. 1 ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med 171 (2005), 912–930.
2. 2 An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med 184 (2011), 602–615.
3. 3 Smith, A.D., Cowan, J.O., Brassett, K.P., Herbison, G.P., Taylor, D.R., Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 352 (2005), 2163–2173.
4. 4 Dweik, R.A., Sorkness, R.L., Wenzel, S., Hammel, J., Curran-Everett, D., Comhair, S.A., et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 181 (2010), 1033–1041.
5. 5 Matsunaga, K., Yanagisawa, S., Hirano, T., Ichikawa, T., Koarai, A., Akamatsu, K., et al. Associated demographics of persistent exhaled nitric oxide elevation in treated asthmatics. Clin Exp Allergy 42 (2012), 775–781.
6. 6 Sugiura, H., Komaki, Y., Koarai, A., Ichinose, M., Nitrative stress in refractory asthma. J Allergy Clin Immunol 21 (2008), 355–360.
7. 7 Voraphani, N., Gladwin, M.T., Contreras, A.U., Kaminski, N., Tedrow, J.R., Milosevic, J., et al. An airway epithelial iNOS-DUOX2-thyroid peroxidase metabolome drives Th1/Th2 nitrative stress in human severe asthma. Mucosal Immunol 7 (2014), 1175–1185.
8. 8 European Network for Understanding Mechanisms of Severe Asthma. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 22 (2003), 470–477.
9. 9 Bumbacea, D., Campbell, D., Nguyen, L., Carr, D., Barnes, P.J., Robinson, D., et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 24 (2004), 122–128.
10. 10 Ten Brinke, A., Zwinderman, A.H., Sterk, P.J., Rabe, K.F., Bel, E.H., Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 164 (2001), 744–748.
11. 11 Miranda, C., Busacker, A., Balzar, S., Trudeau, J., Wenzel, S.E., Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 113 (2004), 101–108.
12. 12 Contoli, M., Baraldo, S., Marku, B., Casolari, P., Marwick, J.A., Turato, G., et al. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. J Allergy Clin Immunol 125 (2010), 830–837.
13. 13 Van Veen, I.H., Ten Brinke, A., Sterk, P.J., Sont, J.K., Gauw, S.A., Rabe, K.F., et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 32 (2008), 344–349.
14. 14 Matsunaga, K., Ichikawa, T., Oka, A., Morishita, Y., Kanai, K., Hiramatsu, M., et al. Changes in forced expiratory volume in 1 second over time in patients with controlled asthma at baseline. Respir Med 108 (2014), 976–982.
15. 15 Covar, R.A., Spahn, J.D., Murphy, J.R., Szefler, S.J., Progression of asthma measured by lung function in the childhood asthma management program. Am J Respir Crit Care Med 170 (2004), 234–241.
16. 16 An official ATS/ERS statement: asthma control and exacerbations. Am J Respir Crit Care Med 180 (2009), 59–99.
17. 17 Matsunaga, K., Hirano, T., Akamatsu, K., Koarai, A., Sugiura, H., Minakata, Y., et al. Exhaled nitric oxide cutoff values for asthma diagnosis according to rhinitis and smoking status in Japanese subjects. Allergol Int 60 (2011), 331–337.
18. 18 MacNee, W., Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 429 (2000), 195–207.
19. 19 Ricciardolo, F.L., Di Stefano, A., Sabatini, F., Folkerts, G., Reactive nitrogen species in the respiratory tract. Eur J Pharmacol 533 (2006), 240–252.
20. 20 Beckman, J.S., Beckman, T.W., Chen, J., Marshall, P.A., Freeman, B.A., Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 87 (1990), 1620–1624.
21. 21 Sugiura, H., Ichinose, M., Oyake, T., Mashito, Y., Ohuchi, Y., Endoh, N., et al. Role of peroxynitrite in airway microvascular hyperpermeability during late allergic phase in guinea pigs. Am J Respir Crit Care Med 160 (1999), 663–671.
22. 22 Ichikawa, T., Sugiura, H., Koarai, A., Yanagisawa, S., Kanda, M., Hayata, A., et al. Peroxynitrite arguments fibroblast-mediated tissue remodeling via myofibroblast differentiation. Am J Physiol Lung Cell Mol Physiol 295 (2008), 800–808.
23. 23 Amelink, M., de Groot, J.C., de Nijs, S.B., Lutter, R., Zwinderman, A.H., Sterk, P.J., et al. Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol 132 (2013), 336–341.
24. 24 Alving, K., Malinovschi, A., Basic aspects of exhaled nitric oxide. Eur Respir Mon 49 (2010), 1–31.
25. 25 Liu, X., Kohyama, T., Wang, H., Zhu, Y.K., Wen, F.Q., Kim, H.J., et al. Th2 cytokine regulation of type 1 collagen gel contraction mediated by human lung mesenchymal cells. Am J Physiol 282 (2002), 1049–1056.
26. 26 Wen, F.Q., Kohyama, T., Liu, X., Zhu, Y.K., Wang, H., Kim, H.J., et al. Interleukin-4- and interleukin-13-enhanced transforming growth factor-beta2 production in cultured human bronchial epithelial cells is attenuated by interferon-gamma. Am J Respir Cell Mol Biol 26 (2002), 484–490.
27. 27 Guo, F.H., Uetani, K., Haque, S.J., Williams, B.R., Dweik, R.A., Thunnissen, F.B., et al. Interferon gamma and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. J Clin Investig 100 (1997), 829–838.
28. 28 Woodruff, P.G., Modrek, B., Choy, D.F., Jia, G., Abbas, A.R., Ellwanger, A., et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 180 (2009), 388–395.
29. 29 McGrath, K.W., Icitovic, N., Boushey, H.A., Lazarus, S.C., Sutherland, E.R., Chinchilli, V.M., et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 185 (2012), 612–619.
30. 30 Ray, A., Oriss, T.B., Wenzel, S.E., Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol 308 (2015), 130–140.
31. 31 Peters, M.C., Mekonnen, Z.K., Yuan, S., Bhakta, N.R., Woodruff, P.G., Fahy, J.V., Measures of gene expression in sputum cells can identify T2-high and T2-low subtypes of asthma. J Allergy Clin Immunol 133 (2014), 388–394.
32. 32 Seys, S.F., Grabowski, M., Adriaensen, W., Decraene, A., Dilissen, E., Vanoirbeek, J.A., et al. Sputum cytokine mapping reveals an ‘IL-5, IL-17A, IL-25-high’ pattern associated with poorly controlled asthma. Clin Exp Allergy 43 (2013), 1009–1017.
33. 33 Matsunaga, K., Ichikawa, T., Yanagisawa, S., Koarai, A., Hirano, T., Sugiura, H., et al. Clinical application of exhaled breath condensate analysis in asthma: prediction of FEV1 improvement by steroid therapy. Respiration 78 (2009), 393–398.
34. 34 Donnely, L.E., Barnes, P.J., Expression and regulation of inducible nitric oxide synthase from human primary airway epithelial cells. Am J Respir Cell Mol Biol 26 (2002), 144–151.
35. 35 Lundberg, J.O., Weitzberg, E., Rinder, J., Rudehill, A., Jansson, O., Wiklund, N.P., et al. Calcium-independent and steroid-resistant nitric oxide synthase activity in human paranasal sinus mucosa. Eur Respir J 9 (1996), 1344–1347.
36. 36 Kanemitsu, Y., Ito, I., Niimi, A., Izuhara, K., Ohta, S., Ono, J., et al. Osteopontin and periostin are associated with a 20-year decline of pulmonary function in patients with asthma. Am J Respir Crit Care Med 190 (2014), 472–474.
37. 37 Goleva, E., Hauk, P.J., Boguniewicz, J., Martin, R.J., Leung, D.Y., Airway remodeling and lack of bronchodilator response in steroid-resistant asthma. J Allergy Clin Immunol 120 (2007), 1065–1072.
38. 38 Gupta, A., Sjoukes, A., Richards, D., Banya, W., Hawrylowicz, C., Bush, A., et al. Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma. Am J Respir Crit Care Med 184 (2011), 1342–1349.
39. 39 Smith, A.D., Cowan, J.O., Brassett, K.P., Filsell, S., McLachlan, C., Monti-Sheehan, G., et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 172 (2005), 453–459.
40. 40 Pijnenburg, M.W., Hofhuis, W., Hop, W.C., De Jongste, J.C., Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 60 (2005), 215–218.
41. 41 Dijkstra, A., Vonk, J.M., Jongepier, H., Koppelman, G.H., Schouten, J.P., ten Hacken, N.H., et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax 61 (2006), 105–110.
42. 42 Lee, J.H., Haselkorn, T., Borish, L., Rasouliyan, L., Chipps, B.E., Wenzel, S.E., Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest 132 (2007), 1882–1889.
43. 43 Matsunaga, K., Akamatsu, K., Miyatake, A., Ichinose, M., Natural history and risk factors of obstructive changes over a 10-year period in severe asthma. Respir Med 107 (2013), 355–360.